WANG Ying, ZHANG Xiao-qi. DAWNA-1 Study: Efficacy Analysis of Dalpiciclib Plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 83-87. DOI: 10.12019/j.issn.1671-5144.2023.02.004
|
Citation:
|
WANG Ying, ZHANG Xiao-qi. DAWNA-1 Study: Efficacy Analysis of Dalpiciclib Plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 83-87. DOI: 10.12019/j.issn.1671-5144.2023.02.004
|
WANG Ying, ZHANG Xiao-qi. DAWNA-1 Study: Efficacy Analysis of Dalpiciclib Plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 83-87. DOI: 10.12019/j.issn.1671-5144.2023.02.004
|
Citation:
|
WANG Ying, ZHANG Xiao-qi. DAWNA-1 Study: Efficacy Analysis of Dalpiciclib Plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 83-87. DOI: 10.12019/j.issn.1671-5144.2023.02.004
|
DownLoad: